8-K: Mirum Pharmaceuticals Reports Strong 2025 Results, Positive 2026 Outlook

Mirum Pharmaceuticals announced robust 2025 financial results, exceeding $521 million in net product sales, and provided an optimistic 2026 guidance with multiple key pipeline readouts anticipated.

Summary

• Mirum Pharmaceuticals reported total net product sales of $521.3 million for the full year ended December 31, 2025, a significant increase from $336.4 million in 2024.
• LIVMARLI net product sales reached $360.0 million in 2025, with U.S. sales growing 69% year-over-year to $244.7 million.
• Bile Acid Medicines net product sales totaled $161.3 million, representing 31% year-over-year growth.
• The company's net loss significantly improved, decreasing to $23.363 million in 2025 from $87.942 million in 2024.
• Unrestricted cash, cash equivalents, and investments stood at $391.4 million as of December 31, 2025, up from $292.8 million in 2024.
• Mirum provided 2026 guidance, expecting global net product sales of approximately $630 million to $650 million.
• Key pipeline milestones for 2026 include topline data from the Volixibat VISTAS study in PSC (Q2 2026), LIVMARLI EXPAND study (Q4 2026), and Brelovitug AZURE-1 and AZURE-4 studies in HDV (H2 2026).
• The company completed the acquisition of Bluejay Therapeutics, adding worldwide rights to brelovitug for HDV.
• Regulatory approvals were secured for LIVMARLI tablets in the U.S. and Europe for ALGS and PFIC, and in Canada and Japan for various indications.
• FDA approval was also received for CTEXLI for cerebrotendinous xanthomatosis (CTX).

Sentiment

Score: 9

Explanation: StockSavvy.ai views this filing as highly positive due to exceptional commercial growth, a significant reduction in net loss, a strengthened cash position, and a robust, catalyst-rich pipeline with multiple late-stage readouts expected in 2026.

Positives

• Total net product sales for 2025 increased by 55% to $521.3 million from $336.4 million in 2024, demonstrating strong commercial growth.
• LIVMARLI U.S. net product sales grew 69% year-over-year, indicating robust market penetration and demand.
• Net loss significantly narrowed to $23.363 million in 2025 from $87.942 million in 2024, reflecting improved operational efficiency and profitability trajectory.
• Cash, cash equivalents, and investments increased to $391.4 million by year-end 2025, strengthening the company's financial position.
• The company provided strong 2026 global net product sales guidance of $630 million to $650 million, signaling continued growth expectations.
• Multiple late-stage pipeline assets (Volixibat, LIVMARLI, Brelovitug) have significant data readouts expected in 2026, creating a catalyst-rich period.
• Successful acquisition of Bluejay Therapeutics expanded the pipeline with brelovitug for HDV, a high-potential asset with FDA Breakthrough Therapy designation.
• Received several key regulatory approvals and authorizations for LIVMARLI across the U.S., Europe, Canada, and Japan, expanding global market access.
• FDA approval of CTEXLI for CTX further diversifies the commercial portfolio.

Risks

• Risks and uncertainties are associated with Mirum's business in general.
• The impact of geopolitical and macroeconomic events could affect operations and financial results.
• Actual results may differ materially from forward-looking statements due to various risks and uncertainties.

Future Outlook

Mirum Pharmaceuticals anticipates a pivotal 2026, projecting global net product sales between $630 million and $650 million. The company expects four potentially registrational readouts over the next 18 months, including topline data for Volixibat in PSC in Q2 2026, LIVMARLI in additional cholestatic pruritus settings in Q4 2026, and Brelovitug in HDV in H2 2026. Enrollment for the LIVMARLI EXPAND and Volixibat VANTAGE studies is also expected to complete in H1 and H2 2026, respectively.

Management Comments

• "2025 was a year of meaningful progress and execution for Mirum, setting the stage for a pivotal 2026."
• "With the recent addition of brelovitug in HDV, we now expect four potentially registrational readouts over the next 18 months, beginning with topline results from the VISTAS study in PSC in the second quarter."
• "This catalyst-rich period, combined with continued commercial performance and financial discipline, positions us well to deliver for shareholders and patients."

Industry Context

StockSavvy.ai notes that Mirum's strong commercial growth in rare disease treatments, particularly with LIVMARLI, aligns with the broader pharmaceutical industry trend of increasing focus on high-value orphan drugs. The expansion of its pipeline through strategic acquisitions like Bluejay Therapeutics and multiple late-stage clinical readouts positions Mirum as a significant player in the rare liver and infectious disease therapeutic areas, where unmet medical needs remain substantial. The company's ability to secure multiple regulatory approvals across different geographies also highlights its effective global market strategy, a key differentiator in the competitive rare disease landscape.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Likely positive impact due to strong financial performance, reduced losses, increased cash, and a promising pipeline with multiple upcoming catalysts, potentially leading to increased share value.
• Patients: Positive impact through expanded access to approved treatments (LIVMARLI, CTEXLI) and the advancement of several investigational medicines (volixibat, brelovitug, MRM-3379) addressing significant unmet medical needs in rare diseases.
• Employees: Continued company growth, pipeline expansion, and strategic acquisitions suggest a stable and potentially growing work environment with opportunities for professional development.
• Creditors: Improved financial health, including increased cash reserves and reduced net loss, enhances the company's creditworthiness.

Next Steps

• Mirum will host a conference call on February 25, 2026, at 1:30 p.m. PT/4:30 p.m. ET to provide business updates.
• Topline data from the Volixibat VISTAS study in primary sclerosing cholangitis (PSC) is expected in Q2 2026.
• Interim data from the Brelovitug AZURE-1 study in chronic hepatitis delta virus (HDV) is expected in Q2 2026.
• Enrollment in the LIVMARLI EXPAND Phase 3 study for pruritus in additional rare cholestatic conditions is expected to complete in H1 2026.
• Enrollment in the Volixibat VANTAGE study in primary biliary cholangitis (PBC) is expected to complete in H2 2026.
• Topline data from the Brelovitug AZURE-1 and AZURE-4 studies in HDV are expected in H2 2026.
• Topline data from the LIVMARLI EXPAND study is expected in Q4 2026.
• The Annual Report on Form 10-K for the year ended December 31, 2025, is anticipated to be filed today.

Key Dates

Recommendation

Mirum Pharmaceuticals demonstrates exceptional commercial momentum with significant year-over-year revenue growth and a substantial reduction in net loss. The company's robust cash position, coupled with a catalyst-rich pipeline featuring multiple late-stage assets with anticipated data readouts in 2026, positions it for continued strong performance. The strategic acquisition of brelovitug further enhances its long-term growth prospects in high-value rare disease markets. For a seasoned investor, these factors collectively present a compelling 'strong buy' opportunity.

Keywords

Mirum Pharmaceuticals, MIRM, Financial Results, 2025 Earnings, 2026 Guidance, LIVMARLI, Volixibat, Brelovitug, Rare Disease, Cholestatic Pruritus, Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis, Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, Hepatitis Delta Virus, Drug Development, Clinical Trials, Biotechnology, Pharmaceuticals